Search Results 1421-1430 of 19186 for Neutrophil

1. NRG-GY012 “A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, And The Combinations Of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5356 (Capivasertib) In Women With Recurrent, Persistent Or Metastatic Endometrial Cancer. A Multi-Arm Trial For Women With Recurrent Or Persistent Endometrial Cancer” - Mayo Clinic

   Platelet count >= 100 x 10^9/L - Absolute neutrophil count (ANC) >= 1.5 x 10^9/L - Hemoglobin > 9 mg/dL. Serum creatinine =< the institutional upper limit ...

2. Efineptakin alfa (NT-I7) Plus Pembrolizumab for the Treatment of Recurrent Glioblastoma - Mayo Clinic

   * Absolute neutrophil count (ANC) \>= 1500/mm\^3 (obtained =\< 15 days prior to registration) * Platelet count \>= 100,000/mm\^3 (obtained =\< 15 days prior ...

3. A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy - Mayo Clinic

   Absolute neutrophil count ≥ 1,500/μL;; Platelets ≥ 100,000/μL;; Hemoglobin ≥ 0 g/dL;; Serum creatinine ≤ 1.5 xp peur limit of normal (ULN) or calculated ...

4. A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers - Mayo Clinic

   - Absolute neutrophil count >= 1,500/mcL - Hemoglobin >= 9.0 g/dl - Platelets >= 100,000/mcL - Total bilirubin =< 1.5 x institutional upper limit of normal ...

5. Doxorubicin Hydrochloride, Cyclophosphamide, And Paclitaxel With Or Without Bevacizumab In Treating Patients With Lymph Node-Positive Or High-Risk, Lymph Node-Negative Breast Cancer - Mayo Clinic

   Within =< 8 weeks prior to randomization: Absolute neutrophil count >= 1,000/mm^3. Within =< 8 weeks prior to randomization: Platelet count >= 100,000/mm^3.

6. A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302) - Mayo Clinic

   Absolute neutrophil count (ANC) < 2 × 10^9/L (2000 cells/mm^3). Serum creatinine level > 1.5 × ULN or estimated glomerular filtration rate (GFR) < 30 mL/min ...

7. Testing The Use Of The Combination Of Selumetinib And Olaparib Or Selumetinib Alone Targeted Treatment For RAS Pathway Mutant Recurrent Or Persistent Ovarian And Endometrial Cancers, A ComboMATCH Treatment Trial - Mayo Clinic

   - Absolute neutrophil count (ANC) >= 1,500/mcl (within 14 days prior to registration) - Patients must have creatinine clearance estimated of >= 50 mL/min ...

8. A Trial of the Effectiveness and Safety of CVL-865 to Treat Focal Onset Seizures - Mayo Clinic

   White blood cell (WBC) count < 3.0 x 10^9/L Neutrophil count < 2.0 x 10^9/L;; Platelet count < 150 x 10^9/L. Subjects with other abnormal laboratory test ...

9. Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ - Mayo Clinic

   Bone marrow: platelets ≥75 x 109/L, absolute neutrophil count (ANC) ≥1.5 x 109/L, hemoglobin ≥10 g/dL. (Platelets ≥50 x 109/L, ANC ≥1.0 x 109/L ...

10. A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer - Mayo Clinic

    Adequate bone marrow function (Platelets ≥100x10^9/L; Absolute Neutrophil Count (ANC) ≥ 1.5x10^9/L and Haemoglobin ≥ 9.0g/dL). Adequate renal function ...